Cargando…
Drug-development, dose-selection, rational combinations from bench-to-bedside: are there any lessons worth revisiting?
Autores principales: | Bridges, Alexander J., Mehta, Ranjit K., Shukla, Sushmita, Schipper, Matthew J., Lawrence, Theodore S., Nyati, Mukesh K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8169070/ https://www.ncbi.nlm.nih.gov/pubmed/34084277 http://dx.doi.org/10.18632/oncotarget.27931 |
Ejemplares similares
-
Disruptin, a cell-penetrating peptide degrader of EGFR: Cell-Penetrating Peptide in Cancer Therapy
por: Mehta, Ranjit K., et al.
Publicado: (2021) -
The NF1 gene revisited – from bench to bedside
por: Yap, Yoon-Sim, et al.
Publicado: (2014) -
Revisiting Excitotoxicity in Traumatic Brain Injury: From Bench to Bedside
por: Baracaldo-Santamaría, Daniela, et al.
Publicado: (2022) -
Higher medical training in Rheumatology in the UK: any lessons worth learning?
por: Hassell, Andrew
Publicado: (2017) -
Takotsubo Syndrome: From Bench to Bedside and Bedside to Bench
por: Pelliccia, Francesco, et al.
Publicado: (2022)